These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17053312)

  • 1. Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses.
    Ibe S; Fujisaki S; Fujisaki S; Morishita T; Kaneda T
    Microbiol Immunol; 2006; 50(10):765-72. PubMed ID: 17053312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
    Martinez-Picado J; Savara AV; Shi L; Sutton L; D'Aquila RT
    Virology; 2000 Sep; 275(2):318-22. PubMed ID: 10998332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
    Martinez-Picado J; Savara AV; Sutton L; D'Aquila RT
    J Virol; 1999 May; 73(5):3744-52. PubMed ID: 10196268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.
    Suñé C; Brennan L; Stover DR; Klimkait T
    Clin Microbiol Infect; 2004 Feb; 10(2):119-26. PubMed ID: 14759236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.
    Geng QM; Li HP; Bao ZY; Liu YJ; Zhuang DM; Li L; Liu SY; Li JY
    Virol Sin; 2010 Oct; 25(5):316-28. PubMed ID: 20960178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.
    Soares EA; Santos AF; Gonzalez LM; Lalonde MS; Tebit DM; Tanuri A; Arts EJ; Soares MA
    J Antimicrob Chemother; 2009 Nov; 64(5):938-44. PubMed ID: 19710076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
    Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
    J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
    J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.